NasdaqCM:CTSO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Cytosorbents's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTSO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.4%

CTSO

0.2%

US Medical Equipment

0.4%

US Market


1 Year Return

63.1%

CTSO

24.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: CTSO exceeded the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: CTSO exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

CTSOIndustryMarket
7 Day-3.4%0.2%0.4%
30 Day5.3%7.4%6.1%
90 Day-12.5%7.6%8.9%
1 Year63.1%63.1%25.9%24.8%20.5%17.8%
3 Year35.0%35.0%75.8%71.2%42.3%32.9%
5 Year7.2%7.2%143.9%124.8%84.2%63.4%

Price Volatility Vs. Market

How volatile is Cytosorbents's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cytosorbents undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CTSO ($8.3) is trading below our estimate of fair value ($27.87)

Significantly Below Fair Value: CTSO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CTSO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CTSO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTSO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTSO is overvalued based on its PB Ratio (12.6x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Cytosorbents forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

74.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTSO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: CTSO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CTSO's is expected to become profitable in the next 3 years.

Revenue vs Market: CTSO's revenue (33.1% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: CTSO's revenue (33.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cytosorbents performed over the past 5 years?

-12.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTSO is currently unprofitable.

Growing Profit Margin: CTSO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.

Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: CTSO has a negative Return on Equity (-70.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cytosorbents's financial position?


Financial Position Analysis

Short Term Liabilities: CTSO's short term assets ($41.9M) exceed its short term liabilities ($15.7M).

Long Term Liabilities: CTSO's short term assets ($41.9M) exceed its long term liabilities ($9.3M).


Debt to Equity History and Analysis

Debt Level: CTSO's debt to equity ratio (62.2%) is considered high.

Reducing Debt: Insufficient data to determine if CTSO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTSO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cytosorbents's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.4yrs

Average management tenure


CEO

Phillip Chan (50 yo)

11.75yrs

Tenure

US$1,404,376

Compensation

Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of CytoSorbents Incorporated since January 2009 and served as its President until 2020. Dr. Chan serves as a Partner of NJTC Venture Fu ...


CEO Compensation Analysis

Compensation vs Market: Phillip's total compensation ($USD1.40M) is about average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Phillip Chan
CEO, President & Director11.75yrsUS$1.40m0.97%
$ 3.5m
Vincent Capponi
President & COO0.42yrUS$1.17m0.34%
$ 1.2m
Kathleen Bloch
CFO & Secretary7.42yrsUS$999.85k0.28%
$ 998.5k
Christian Steiner
Senior Vice President of Sales & Marketing8.33yrsno datano data
Christopher Cramer
Vice President of Business Development7.5yrsno datano data
Efthymios Deliargyris
Chief Medical Officer0.42yrno datano data
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant3.33yrsUS$97.32kno data

7.4yrs

Average Tenure

62yo

Average Age

Experienced Management: CTSO's management team is seasoned and experienced (7.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Phillip Chan
CEO, President & Director11.75yrsUS$1.40m0.97%
$ 3.5m
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant3.33yrsUS$97.32kno data
Al Kraus
Independent Chairman of the Board11.75yrsUS$311.00k0.13%
$ 462.7k
Alan Sobel
Independent Director5.92yrsUS$168.00k0%
$ 0
Edward Jones
Independent Director13.5yrsUS$156.95k0.022%
$ 78.8k
Joseph Parrillo
Member of Critical Care Advisory Boardno datano datano data
John Kellum
Member of Critical Care Advisory Boardno datano datano data
Ronald Maier
Chairman of the Trauma Advisory Boardno datano datano data
Mitchell Cohen
Member of Trauma Advisory Boardno datano datano data
Raul Coimbra
Member of Trauma Advisory Boardno datano datano data
Ernest Moore
Member of Trauma Advisory Board7.5yrsno datano data
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board6.08yrsno datano data

7.5yrs

Average Tenure

72yo

Average Age

Experienced Board: CTSO's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.


Top Shareholders

Company Information

Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytosorbents Corporation
  • Ticker: CTSO
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$358.210m
  • Shares outstanding: 43.16m
  • Website: https://www.cytosorbents.com

Number of Employees


Location

  • Cytosorbents Corporation
  • 7 Deer Park Drive
  • Suite K
  • Monmouth Junction
  • New Jersey
  • 8852
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTSONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2006
HQE1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2006

Biography

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:17
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.